Amyloid and <i>APOE ε4</i> interact to influence short-term decline in preclinical Alzheimer disease
Elizabeth C. Mormino(Allen Institute for Brain Science), Aaron P. Schultz(Harvard University), Willem Huijbers(Massachusetts General Hospital), Rebecca A. Betensky(Harvard University), Andrew Ward(Brigham and Women's Hospital), Trey Hedden(Harvard University), Dorene M. Rentz(Brigham and Women's Hospital), Reisa A. Sperling(Harvard University), Keith A. Johnson(Brigham and Women's Hospital)
Cited by 302
Related Papers
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
|Alzheimer s & Dementia|2018|10.4k
Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
|Alzheimer s & Dementia|2011|7.1k
Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease
|New England Journal of Medicine|2012|3.8k
A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease
|Alzheimer s & Dementia|2014|3.1k